← Human Trials & Peer-Reviewed Studies
The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant
Plain-language guide to PMID 35263421 (2022): randomized controlled trial study of Copper (Supplement).
Key Facts
- PMID
- 35263421
- Journal
- The Journal of infectious diseases
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Tanko RF et al. (20 authors)
- DOI
- 10.1093/infdis/jiac084
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Copper (Supplement).
The ECHO trial randomized women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intrauterine device (Cu-IUD).
In a substudy of the ECHO trial, the researchers tested the hypothesis that contraceptives influence genital inflammation by comparing cervicovaginal cytokine changes following contraception initiation.
Who Took Part
PubMed tags the participants as women only.
Women (n = 251) from South Africa and Kenya were included.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
Twenty-seven cervicovaginal cytokines were measured by Luminex at baseline, and 1 and 6 months after contraceptive iTanko et alnitiation.
In addition, cytokines were measured preseroconversion in HIV cases (n = 25) and controls (n = 100).
What Was Measured
In a substudy of the ECHO trial, the researchers tested the hypothesis that contraceptives influence genital inflammation by comparing cervicovaginal cytokine changes following contraception initiation.
The subject headings attached to it are Contraception, Contraceptive Agents, Female, Cytokines, Genitalia, HIV Infections, Intrauterine Devices, Copper and Levonorgestrel.
The authors tagged it with the keywords Cu-IUD, DMPA-IM, LNG-implant, inflammation and reproductive tract.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement).
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (The Journal of infectious diseases), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.